Oligomerix
Mr. Bluestein serves as Senior Managing Director of R.H.Bluestein & Co., an independent Registered Investment Advisor with offices in Birmingham, Michigan and New York City. Jeff’s role at the company is to aid in the management of assets of high net worth individuals and private institutions. The firm manages assets using a mix of traditional equities and fixed income securities as well as private equity opportunities. Jeff graduated from Cornell University with a Bachelor of Science and from the Ross School of Business at the University of Michigan with an Masters in Business Administration. Prior to joining the firm, Jeff has been employed by Newman Financial Services, a boutique investment bank as well as Goldman, Sachs & Co.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.